Aldosterone and the mineralocorticoid receptor

European Heart Journal, Supplement

Volumn 13, Issue SUPPL. B, 2011, Pages

  Messaoudi, Smail ^a,b   Jaisser, Frédéric ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Aldosterone; Angiotensin II; Cardiovascular disease; Mineralocorticoid receptors; Oxidative stress

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ANGIOTENSIN II; EPLERENONE; FAD 286; GLUCOCORTICOID; HORMONE RECEPTOR BLOCKING AGENT; HYDROCORTISONE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR BLOCKING AGENT; OXYGENASE INHIBITOR; SODIUM CHLORIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD VESSEL; CARDIOMYOPATHY; HEART; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INFLAMMATION; KIDNEY; KIDNEY FIBROSIS; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING;

EID: 79959517161     PISSN: 1520765X     EISSN: 15542815     Source Type: Journal    
DOI: 10.1093/eurheartj/sur004     Document Type: Article

References (60)

1. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T. [Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism]. Experientia 1953;9:333-335.
2. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67:1355-1364.
3. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994;24:30-36. (Pubitemid 24195401)
4. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-575. (Pubitemid 23208145)
5. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosteroneinduced inflammation in the rat heart : role of oxidative stress. Am J Pathol 2002;161:1773-1781. (Pubitemid 35265535)
6. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007;113:267-278. (Pubitemid 47372685)
7. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006;20: 1546-1548.
8. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992;120:893-901. (Pubitemid 23002899)
9. Wang Q, Clement S, Gabbiani G, Horisberger JD, Burnier M, Rossier BC, Hummler E. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol 2004;286: F1178-F1184. (Pubitemid 38656375)
10. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De Angelis N, Morineau G, dEstienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004;110: 1819-1825. (Pubitemid 39299224)
11. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Nguyen Dinh Cat A, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005;111:3025-3033. (Pubitemid 40847778)
12. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005;111: 420-427. (Pubitemid 40204425)
13. Wang D, Liu YH, Yang XP, Rhaleb NE, Xu J, Peterson E, Rudolph AE, Carretero OA. Role of a selective aldosterone blocker in mice with chronic heart failure. J Card Fail 2004;10:67-73. (Pubitemid 38885720)
14. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007; 292:R946-R954. (Pubitemid 46207752)
15. Di Zhang A, Nguyen Dinh Cat A, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, Delcayre C, Samuel JL, Jaisser F. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 2008;52:1060-1067.
16. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-1248. (Pubitemid 40523144)
17. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001;88: 906-909, A908. (Pubitemid 32995932)
18. Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, Wu CK, Yu CC, Wang YC, Lai LP, Lin JL. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol;55:758-770.
19. Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, Yang B. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol;159: 1584-1594.
20. Lalevee N, Rebsamen MC, Barrere-Lemaire S, Perrier E, Nargeot J, Benitah JP, Rossier MF. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 2005;67:216-224. (Pubitemid 40943614)
21. Gomez AM, Rueda A, Sainte-Marie Y, Pereira L, Zissimopoulos S, Zhu X, Schaub R, Perrier E, Perrier R, Latouche C, Richard S, Picot MC, Jaisser F, Lai FA, Valdivia HH, Benitah JP. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009;119: 2179-2187.
22. De Mello WC. Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst 2006;7:40-46. (Pubitemid 43891244)
23. Qu J, Volpicelli FM, Garcia LI, Sandeep N, Zhang J, Marquez-Rosado L, Lampe PD, Fishman GI. Gap junction remodeling and spironolactonedependent reverse remodeling in the hypertrophied heart. Circ Res 2009;104:365-371.
24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
25. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. (Pubitemid 36384098)
26. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-182.
27. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008;102:1359-1367.
28. Jaisser F, Swynghedauw B, Delcayre C. The mineralocorticoid receptor in heart: differential effects in different cells. Hypertension 2011;57:679-680.
29. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, Frantz S, Ertl G, Bauersachs J. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation;123:400- 408.
30. Lother AB, Berger S, Gilsbach R, Roesner S, Ecke A, Barreto F, Bauersachs J, Schutz G, Hein L. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function after chronic pressure overload. Hypertension 2011;57:746-754.
31. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009;54:537-543.
32. Ambroisine ML, Favre J, Oliviero P, Rodriguez C, Gao J, Thuillez C, Samuel JL, Richard V, Delcayre C. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 2007; 116:2435-2443. (Pubitemid 350145078)
33. Favre J, Gao J, Remy-jouet I, Ouvrard-Pascaud A, Dautreaux B, Escoubet B, Thuilliez C, Jaisser F, Richard V. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circul Physiol 2011; in press.
34. Lal A, Veinot JP, Leenen FH. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res 2004;64:437-447. (Pubitemid 39505423)
35. Huang BS, White RA, Ahmad M, Tan J, Jeng AY, Leenen FH. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Cardiovasc Res 2009;81:574-581.
36. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J;24:2454-2463.
37. Perrier R, Richard S, Sainte-Marie Y, Rossier BC, Jaisser F, Hummler E, Benitah JP. A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J Physiol 2005;569(Pt 1): 153-162. (Pubitemid 41701382)
38. Rossier MF, Lenglet S, Vetterli L, Python M, Maturana A. Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 2008;52: 721-728.
39. Latouche C, Sainte-Marie Y, Steenman M, Castro Chaves P, Naray-Fejes-Toth A, Fejes-Toth G, Farman N, Jaisser F. Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology;151:4467-4476.
40. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009;54:1306-1312.
41. Young M, Funder JW. Aldosterone and the heart. Trends Endocrinol Metab 2000;11:224-226. (Pubitemid 30603168)
42. Fjeld CC, Birdsong WT, Goodman RH. Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA 2003;100:9202-9207. (Pubitemid 37033907)
43. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009;53:286-290.
44. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 2001;280:F181-F192.
45. Konishi A, Tazawa C, Miki Y, Darnel AD, Suzuki T, Ohta Y, Tabayashi K, Sasano H. The possible roles of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Steroid Biochem Mol Biol 2003;85:439-442. (Pubitemid 37011119)
46. Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, Honsho S, Nishikawa S, Mano A, Shiraishi J, Yamada H, Takahashi T, Matoba S, Kobara M, Matsubara H. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 2007;30:427-437. (Pubitemid 46958893)
47. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008;14:1370-1376.
48. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005;96: 643-650. (Pubitemid 40478331)
49. Ito K, Hirooka Y, Sunagawa K. Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload. J Hypertens;28:1449-1458.
50. Grossmann C, Gekle M. Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance. Steroids 2008;73: 973-978.
51. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999;33:981-986. (Pubitemid 29186395)
52. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008;28:1511-1518.
53. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pflugers Arch 2009;458: 231-246.
54. Veliotes DG, Woodiwiss AJ, Deftereos DA, Gray D, Osadchii O, Norton GR. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation. Hypertension 2005;45:914-920. (Pubitemid 40628937)
55. Bauer R, Blain A, Greally E, Lochmuller H, Bushby K, MacGowan GA, Straub V. Attenuation of adverse cardiac effects in prednisolonetreated delta-sarcoglycan-deficient mice by mineralocorticoidreceptor- antagonism. Neuromuscul Disord;20:21-28.
56. Shimoni Y, Chen K, Emmett T, Kargacin G. Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart. Br J Pharmacol 2008;154:675-687. (Pubitemid 351744944)
57. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008;117:2253-2261.
58. Arai K, Nakagomi Y, Iketani M, Shimura Y, Amemiya S, Ohyama K, Shibasaki T. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum Genet 2003;112: 91-97. (Pubitemid 36869121)
59. Cavallari LH, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. Pharmacotherapy;30:1-9.
60. Mohammed SF, Ohtani T, Korinek J, Lam CS, Larsen K, Simari RD, Valencik ML, Burnett JC Jr, Redfield MM. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via nongenomic effects. Circulation;122:370-378.